Tuesday, June 25, 2024

Case report form in BEHR (blended EMR and PHR format) of 88F with altered sensorium and heart failure (project altered sensorium: PI Dr Haripriya)

Dr Haripriya , PI (principal investigator) for the "altered sensorium outcomes" project, selected this patient participant when the patient first presented in Feb 2023 and the intern Dr Gnana Prasad (2017 mbbs entry?) wrote the case details which I have further deidentified and pasted below:


February 2023
A  88 yrs old  Female  presented to casualty with
C/o  irrelevant talk and altered mental status since 10 days
Shortness of Breath since 3 days 
Cough since 3 days 

HISTORY OF PRESENT ILLNESS:
Patient was  asymptomatic 10 days ago and then developed altered mental status on & off and her speech being non cohorent  at times and later becoming normal by herself , each episode  lasting for 10- 15 mins .
Productive cough 2 days ago 
Now dry cough
Shortness of breath since  3 days  initially grade III
progressed  grade IV in these  3 days. 
Later went to outside hospital and 2 D echo was done  
2 D echo ( CAD , LAD + territor) , Global Hypokinesia , Severe LV dysfunction 
No history of chest pain , palpitations , giddiness.

HISTORY OF PAST ILLNESS:

N/ K/C/O HTN , DM , CVA , Epilepsy , Asthma 

PERSONAL HISTORY: 
DIET: MIXED 
APPETITE: DECREASED 
BOWEL AND BLADDER MOVEMENTS: REGULAR 
SLEEP: ADEQUATE 
ADDICTIONS: NO

ON EXAMINATION :

PATIENT IS CONSCIOUS NON COHERENT AND COOPERATIVE 

GENERAL EXAMINATION:
NO PALLOR ICTERUS CYANOSIS CLUBBING LYMPHADENOPATHY EDEMA 


VITALS:
BP- 90/50 MMHG
PR- 85BPM
RR- 24CPM
SPO2- 88% @RA , 94% on HIGH FLOW O2
GRBS- 126MG/DL

CVS- S1 S2 HEARD. NO MURMURS 

RS -Barrel shaped chest , BAE + 
        Crepts + , Left IAA ,ISA
       Bronchial  breath sounds , 
        Right ISA


PA - soft , nontender
TEMP - AFEBRILE 
CNS : Not oriented to T /P/P
           NFD

Urinary Electrolytes:
Chloride - 94
Potassium - 30
Sodium - 127

GAIT - NORMAL 
GCS- E4V5M6



PROVISIONAL DIAGNOSIS:
HEART FAILURE WITH REDUCED EJECTION FRACTION SECONDARY TO CAD ?
WITH ANT. WALL MI ?
WITH TRUE HYPONATREMIA 
AND WITH RIGHT MILD PLEURAL EFFUSION ?

INVESTIGATIONS:
ON 3/04/2023
ECG :



Arterial blood gas :

Chest X -RAY :


SERUM ELECTROLYTEs :



TROP I :




HEMOGRAM:




CHEST X RAY  LATERAL VIEW :






2D ECHO REPORT 

2D ECHO:
Rx :

1. INJ. LASIX 20 mg /IV /BD
  
2. T . ECOSPRIN GOLD PO/ H/S
       75/75/10 mg 

3. T. MET XL 25 mg PO /OD

4.  INJ. NORAD - DS ( 2 ampoules  in 46 ml NS /IV 
                                           @ 6 ml / hr )
5. SYP . POTKLOR 15 ml  in 1 glass of water PO / TID

6. Fluid restriction

7. O2 supplementation to maintain
        Sp O 2 > 94%
 
ON 4/02/23

 Patient is oriented to time and place 
  
VITALS

Bp:- 80/40 mmhg 
Pr :- 78 bpm
RR : 22 cycles / min
SpO2: 88% @RA , 94% on HIGH FLOW O2

Rx:

1. T . ECOSPRIN GOLD PO/ H/S
       75/75/10 mg 

2. T. MET XL 25 mg PO /OD

3. INJ. NORAD - DS ( 2 ampoules  in 46 ml NS /IV 
                                           @ 6 ml / hr )
4. SYP . POTKLOR 15 ml  in 1 glass of water PO / TID

5. Fluid restriction

6. T. SPIRINOLACTONE 50 mg /PO/OD

7. O2 supplementation to maintain
        Sp O 2 > 92%
8. Nebulization with SALBUTAMOL 1 respule /stat /
9. Inj. HEPARIN 4000IU/IV/BD


INVESTIGATIONS:


Hospital timeline:



Once the interns shared their web logged EMR data with the other team members in PaJR for further team based learning, many more themes started emerging with more clarity around the patient's time line contributed by Dr Deepika who is a PI for another departmental project on cerebral stroke outcomes.

The team based learning conversations are pasted below from the app where these took place as part of the PaJR decision making workflow that also includes the patient relatives:

21/02/23, 12:54 - Messages and calls are end-to-end encrypted. No one outside of this chat, not even the global managers of this App, can read or listen to them. 

04/02/23, 10:50 - ~
 � created group "88F - CAD  Cerebral infarct hyponatremia recovered from ventilator"

21/02/23, 12:54 - H joined using this group's invite link

21/02/23, 12:54 - Dr Vamshi Pg Gmed2 joined using this group's invite link

21/02/23, 12:54 - Dr Vinay Pg Gmed 2 joined using this group's invite link
21/02/23, 12:55 - Dr Durga Krishna Pg Med2 joined using this group's invite link
21/02/23, 12:56 - Dr Shashikala Pg Med joined using this group's invite link
21/02/23, 12:58 - Dr Shashikala Pg Med: 
Dr Gana Prasad's link 
25/02/23, 10:48 - Dr.Deepika Ch: https://manaswinibhootharaju153.blogspot.com/2023/02/88-yrs-old-female-came-to-casualty-with.html

25/02/2023

PaJR soap updates

Patient currently in Icu
Unit1

S:
Stools not passed
Fever spike 101 f @ 2am

O:
O/E: conscious coherent and oriented to place
Temp- 98f
Bp-80/40 mmhg on NORAD 12 ml/hr and DOBUT 9ml/hr
Pr- 106 bpm
Rr-20cpm
Spo2-96 % on 2l oxygen
Grbs: 97mg/dl

Systemic Examination:

Cardiovascular System : S1, S2 heard, palpable p2 +

Respiratory System : decreased air entry on rt side
AA Crepts positive on left side

Central Nervous System : patient is oriented to place
E4v5m6

Per abdomen : soft, 4/min

A:

ALTERED SENSORIUM secondary to ?UREMIC ENCEPHALOPATHY
HYPOXIC ENCEPHALOPATHY WITH HEART FAILURE WITH MIDRANGE EJECTION FRACTION(EF 42%)
 SECONDARY TO ANTERIOR WALL MI
WITH HYPERKALEMIA SECONDARY TO INCREASED INTAKE OR KIDNEY INJURY
WITH ILD WITH L. LOWER-LOBE CONSOLIDATION  with URETHRAL CARUNCLE
WITH G1 BED SORE

 P:

1. 200ml milk 4th hourly
2. 100ml water 4 th hourly
3. Inj. NORAD 14mg in 46 ml ns @1 ml/hr ( increase or decrease to maintain MAP OF 55 mmhg
4. Inj DOBUTAMINE 250mg in 50ml NS @ 8 ml/hr
5. T. Carvidolol 3.125 mg/Rt/OD
6. INJ. Ceftriaxone 1gm/iv/bd
7. Inj. LASIX 40mg BD/IV/BD(if sbp> 110 without narad support
8. T. ECOSPIRIN 75/75/10 mg rt OD
9. Neb with IPRAVENT TID
10. T.NODOSIS 500mg iv bd
11. O2 inhalation to maintain spo2 >94
12. Monitor vitals
25/02/23, 16:47 - Dr Rakesh Biswas Sir HOD added Dr Ajay Gen Med Pg
25/02/23, 16:50 - Dr Rakesh Biswas Sir HOD: EF is around 30%

It's likely that she had a PRES

@ team member@ team member@team member@team member 

In the context of this patient who presented with recurrent altered sensorium can you review the literature around similar presentations in PRES

Anything in her radiology to suggest that? Is the posterior cerebral structure more commonly involved in PRES? If yes why?

25/02/23, 18:46 - Dr.Deepika Ch: 

Here's a detailed history of the patient's event timeline:

88 year old female

Her daily routine-

A joyful 88 year old female starts her day at 6am with a cup of tea/ coffee and then she does her routines like cleaning the house, cooking
Has her breakfast at 9 to 10am which is cooked by herself
She then takes rest while watching TV or even talking to her neighbours
Lunch at around 2 pm which most of the time is rice,Dal and some curry
She then tries to relax herself and find pleasure in talking to her neighbours in the porch for which she even refused to stay at her sons house 🏠
Cooks her own food and goes to sleep at around 9pm
This routine of her continued till 6 months back then
She developed disturbances in her behaviour with increased irritability , decreased interaction with people
Slowly later there is increased self talk

4 months back on one fine day patient was found walking towards the opposite village at night ,neighbours recognising her have informed the family and made her stay overnight ,she was slightly agitated and irritable saying she was heading to village to get her debts back from the people she has given to.

2months back patient remained more or less the same mentally ,then she had increased forgetfulness
Often started forgetting to turnoff the gasstove,switching off lights/fans, close the doors

She developed involuntary movements of limbs (upperlimbs) which were on and off (no seizure like activity),altered sensorium and was taken to local practioner ,neuroimaging(ct) was done and found to be normal which resolved after 2-3 days but involuntary movements didn't subside though decreased intensity

Patient had an episode of weakness of lowerlimbs ,Inability to walk her son being local practioner got investigated for Hypokalemia found to have K-2.0 and was added dietary supplementation and syp potchlor

1month back February 1st week patient had shortness of breath ,altered sensorium and brought to our hospital and treated  heartfailure, hyponatremia.patient sensorium improved and was stable during discharge

10days back patient developed similar episode and got investigated outside and found to have ?ILD on hrct
Patient then was brought here for further management .

25/02/23, 21:30 - Dr Haripriya Pg: Sir can be think it as PRES
As we are not sure about her vision disturbance
And no seizures
And basically as PRES is a clinicoradiological diagnosis
We are not having radiological evidence and in PRES there is refractory headache which is not present in this patient
And she is having fluctuating sensorium,and I think PRES wont develop such fluctuations in sensorium
As in previous admission she is having Ef of 30%,and her sensorium improved at admission,and with the same Ef was normal for 20 days..

25/02/23, 21:45 - Dr Saicharan Pg Gmed2: Good thought process 👏🏻👏🏻
Given her clinical condition with fluctuating sensorium PRES is a good possibility but can it happen with normal blood pressure...? @919704090596 i think her admission bp is normal..
The paradox here is initially we also thought altered sensorium is due to hypoxia and uremic but even after hypoxia correction her sensorium not improved and surprisingly her sensorium improved ( though not completely normal ) even after worsened urea ( from 102 to 160 ) pointing less possibility of Uremic encephalopathy..!!

@team member : Good thesis case to be included in your thesis.. also look into other causes too

25/02/23, 21:51 - Dr.Deepika Ch: Sir how come it not be her neurodegenerative condition which could have worsened acutely
( acute stress condition )
 
As I could see her condition in toto which isn't normal even prior to this episode

Others too (uremia,hypoxemia)which could have added to her already affected brain/ sensorium?!

25/02/23, 21:55 - Dr Haripriya Pg: What u think is the stressor

25/02/23, 22:00 - Dr.Deepika Ch: Any stressor like
Hypoxemia 2° to heart failure,uremia,infections,MI...

25/02/23, 22:08 - Dr Haripriya Pg: She is having reduced EF since 1 month and uremia we are not sure about the urea levels at her home,bcz now her urea is 150 and she is oriented
And infections,not at all
She is having fever just bcz of thromboprophylaxis

25/02/23, 22:09 - Dr Haripriya Pg: Thrombophlebitis *

25/02/23, 22:10 - Dr Haripriya Pg: MI she is having since last admission

25/02/23, 22:16 - Dr Saicharan Pg Gmed2: @team member ,  as you are altered sensorium specialist what about your thoughts on Neurodegenerative condition leading to her altered sensorium..??

25/02/23, 22:18 - Dr.Deepika Ch: How sure are we regarding her prior status!

Agreed we r not sure of the trigger

Her changes in sensorium were from past few months which couldn't be explained by the uremia,hypoxia!( as it was normal ?!)

25/02/23, 22:20 - Dr Saicharan Pg Gmed2: What wasn't normal when you saw her in toto in her previous history....?? Can you elaborate on this please

25/02/23, 22:36 - Dr Haripriya Pg: Am sure regarding her sensorium😊

25/02/23, 22:49 - Dr.Deepika Ch: In sense the cause??

25/02/23, 23:31 - Dr Rakesh Biswas Sir HOD: What radiologic evidence is lacking for PRES?

What is the cerebrovascular pathology in PRES?

It appears to be cerebral vasculopathy also mimicking a neurodegenerative disorder @team member?

25/02/23, 23:36 - Dr Haripriya Pg: Neurodegenerative disorder
Is it waxing and waning sir

25/02/23, 23:37 - Dr Rakesh Biswas Sir HOD: Can be due to other factors. Check out the patient descriptions in @team members's last publication

25/02/23, 23:37 - Dr Haripriya Pg: Okay sir

27/02/23, 17:02 - Dr.Deepika Ch: Yes sir

27/02/23, 17:06 - Dr Saicharan Pg Gmed2: Please share the literature about PRES occuring with normal blood pressure ( age adjusted normal BP )...?

27/02/23, 19:22 - Dr Rakesh Biswas Sir HOD added Dr Prachethan Jr Gmed

27/02/23, 19:23 - Dr Rakesh Biswas Sir HOD changed the group description

27/02/23, 19:25 - Dr Rakesh Biswas Sir HOD added Dr Himaja Jr Gmed

27/02/23, 19:23 - Dr Rakesh Biswas Sir HOD: @tm @tm Please share today's trend-chart soap update for this and every ICU AMC patient asap

27/02/23, 19:26 - Dr Rakesh Biswas Sir HOD changed the group name from "88F - CAD  Cerebral infarct hyponatremia recovered from ventilator" to "88F CAD  Cardiogenic shock Cerebral infarct hyponatremia altered sensorium Telengana PaJR"

27/02/23, 19:24 - Dr Rakesh Biswas Sir HOD changed the group description

27/02/23, 19:28 - Dr Rakesh Biswas Sir HOD: @tm  @tm  @tm  Ask Intern manasvini to crop out the identifiers from the echo report here 👇

https://manaswinibhootharaju153.blogspot.com/2023/02/88-yrs-old-female-came-to-casualty-with.html?m=1

27/02/23, 19:30 - Dr Rakesh Biswas Sir HOD: Also I think we shouldn't share clinical breast images of women unless absolutely necessary so please review that and crop or take with appropriate gown

27/02/23, 19:37 - Dr Rakesh Biswas Sir HOD changed this group's icon

27/02/23, 19:33 - Dr Rakesh Biswas Sir HOD: IMG-20230227-WA0079.jpg (file attached)

27/02/23, 19:35 - Dr Rakesh Biswas Sir HOD: IMG-20230227-WA0080.jpg (file attached)

27/02/23, 19:36 - Dr Rakesh Biswas Sir HOD: Another fever chart dated 3/2/23 uploaded by Manaswini (add her to this group) shows identifiers. Ask to remove asap @tm  @tm 

27/02/23, 19:45 - +91 96768 24264 joined using this group's invite link
27/02/23, 19:45 - Dr. Dinesh Datta joined using this group's invite link
27/02/23, 20:04 - Dr Navya Gen Med Pg joined using this group's invite link

27/02/23, 20:16 - Dr.Deepika Ch: Commonly, PRES evolves over a matter of hours, with the most common presenting symptoms being seizures, disturbed vision, headache, and altered mental state (4) (Figure 1). More than 70% of patients with PRES are hypertensive, though a significant proportion have normal or only mildly raised blood pressure (3-7).
trigger is usually identifiable—most commonly, acute hypertension—but patients often have other comorbidities that may predispose them to developing PRES. Peak systolic blood pressure is usually between 170 mmHg and 190 mmHg (2,4), but 10% - 30% of patients have normal or only mildly elevated blood pressure (2,4). In PRES, the causes of acute hypertension are commonly acute kidney injury or eclampsia (3,4), but hypertension is also reported in cases of autonomic disturbance, for example Guillain-Barré syndrome (10,11), and after illicit drug use

27/02/23, 20:18 - Dr Rakesh Biswas Sir HOD: 👆Answer first two @tm 

27/02/23, 20:20 - Dr.Deepika Ch: The exact pathophysiological mechanism of PRES is still unclear. Three hypotheses have been proposed till now, which include (i) Cerebral vasoconstriction causing subsequent infarcts in the brain, (ii) Failure of cerebral autoregulation with vasogenic edema, and (iii) Endothelial damage with blood–brain barrier disruption further leading to fluid and protein transudation in the brain. The distinct imaging patterns in PRES are represented in Table Table22 [5]. The reversible nature of PRES has been challenged recently based on new reports of permanent neurological impairment and mortality reaching 15%.

hypertension associated or drug-induced PRES, the effective therapy includes withdrawal of offending agent, immediate control of blood pressure, anti-convulsive therapy and temporary renal replacement therapy (hemodialysis/peritoneal dialysis) if required. In Systemic lupus erythematosus-related PRES, aggressive treatment with corticosteroids and cyclophosphamide is effective. Corticosteroids may improve vasogenic edema, but there is no solid evidence for usage in PRES.

01/03/23, 18:53 -Patient advocate: Dear Dr. Rakesh sir & Dr. Mohd Zain sir and team (all PG's and Interns), I wanted to express my deepest gratitude for the exceptional care you provided to my mother during her recent treatment. Your expertise, compassion, and dedication were truly remarkable, and our family is forever grateful for your hard work and commitment to her health. Thank you from the bottom of our hearts.

***********************************************************************************
From 

01/03/23, 19:00 - Dr Saicharan Pg Gmed2: Thank you.

01/03/23, 19:01 - Dr Saicharan Pg Gmed2: Please don't forget to share her daily updates here

01/03/23, 19:05 Patient advocate: Sure Sir

01/03/23, 19:13 - Dr Saicharan Pg Gmed2: Please don't share patient identifiers in the public domain.

01/03/23, 19:13 - Dr Saicharan Pg Gmed2: This is to maintain patient privacy and confidentiality..

01/03/23, 19:24 -Patient advocate: Ok Sir

Discharge summary of the first admission from Feb 3 to Feb 8 2023:
Finally the patient was discharged after a stay of 5 days and while intern Dr Gana Prasad typed the discharge summary, it was guided by residents Dr Haripriya and Dr Chandana. The caps lock is a feature of the hospital EMR that is currently limited to billing and discharge summaries print out production. The PaJR discussion pasted above is where the actual core EHR content and insights for thematic analysis takes shape.

DEPARTMENT OF GENERAL-MEDICINE

DISCHARGE SUMMARY of the first admission 

Pay Type : Paying
Age/Gender : 86 Years/Female
Address :
Discharge Type: Relieved
Admission Date: 03/02/2023 12:13 AM

Diagnosis at discharge:

HEART FAILURE WITH REDUCED EJECTION FRACTION SECONDARY TO CORONARY
ARTERY DISEASE(EF 30%) WITH ANTERIOR WALL MI WITH TRUE HYPONATREMIA
SECONDARY TO SIADH(RESOLVED) AND HYPOKALEMIA (RESOLVED) WITH BILATERAL
LUNG CONSOLIDATION


Case History and Clinical Findings

COMPLAINTS OF Irrelevant TALK AND Altered MENTAL STATUS SINCE 10 DAYS

COMPLAINTS OF SHORTNESS OF BREATH SINCE 3 DAYS
COMPLIANTS OF COUGH SINCE 3 DAYS

HOPI:

PATIENT WAS APPARENTLY ASYMPTOMATIC 10 DAYS AGO AND THEN SHE DEVELOPED
ALTERED MENTAL STATUS ON AND OFF AND HER SPEECH WAS INCOHERENT AT TIMES
AND BECOMING NORMAL ON HER OWN.
EACH EPISODE LASTED 10 MINS
 Page-2

COUGH WAS PRODUCTIVE TYPE 2 DAYS AGO WITH WHITE SPUTUM'MUCOID CONSISTENCY
AND SCANTY IN AMOUNT , NOW IT IS OF DRY TYPE
SHE ALSO HAD SHORTNESS OF BREATH WHICH WAS GRADE III INITILLY AND THEN
PROGRESED TO GRADE IV FOR WHICH SHE WENT TO LOCAL HOSPITAL AND ECHO WAS
DONE- CAD (LAD TERRITORY) GLOBAL HYPOKINESIA, SEVERE LV DYSFUNCTION
NO H/O OTHOPNEA, PAROXYSMAL NOCTURNAL DYSPNOEA , PALPITATIONS, CHEST PAIN,
GIDDINESS
PAST ILLNESS:
NOT A KNOWN CASE OF HTN, DM, CVA, ASTHMA,EPILEPSY, TB
PERSONAL HISTORY:
DIET- MIXED
APPETITE- DECREASED
BOWEL AND BLADDER MOVEMENTS- REGULAR
SLEEP- ADEQUATE
ADDICTIONS- NONE
ON EXAMINATION AT ADMISSION:
PATEINT IS CONSCIOUS, COHERENT, COOPERATIVE
NO PALLOR ICTERUS, CYANOSIS, CLUBBING, LYMPHADENOPATHY, PEDAL EDEMA
BP- 90/50MMHG
PR- 85BPM
RR-24CPM
SPO2- 88%@RA 95% ON 8L OF O2
GRBS- 126MG/DL
CVS-S1 S2 +
RS- BAE+, B/L BASAL CREPTS HEARD
PA- SOFT NON TENDER
CNS- NFD
ON EXAMINATION AT DISCHARGE:
PATEINT IS CONSCIOUS, COHERENT, COOPERATIVE
BP- 90/50MMHG
 Page-3
PR- 72BPM
SPO2- 98%@RA
GRBS- 82MG/DL
CVS-S1 S2 +
RS- BAE+, B/L BASAL CREPTS HEARD, RT IAA CREPTS +, BRONCHIAL BREATH SOUNDS +
PA- SOFT NON TENDER
CNS- NFD

BRIEF COURSE IN HOSPITAL-ON DAY 1 PATIENT PRESENTED WITH ABOVE COMPLAINTS
WAS INITIALLY CONSCIOUS, COHERENT AND COOPERATIVE .AT THE TIME OF ADMISSION
HER BP WAS 90/50 WITH OUTSIDE ECHO SHOWING CAD(LAD TERRITORY) WITH GLOBAL
HYPOKINESIA AND SEVERE LV DYSFUNCTION.THEN DIURETICS AND ANTIPLATELETS
WERE STARTED.MONITORING HER BP AND CARDIOLOGY CONSULTATION WERE TAKEN ON
3/2/23 I/V/O CORONARY ARTERY DISEASE AND CARDIOLOGIST ADVICED INJ.HEPARIN 4000
IU/IV/BD AND TAB.CAVERDILOL 3.125 MG WAS ADVICED AND ADVICE FOLLOWED AND HER
SODIUM AND POTASSIUM LEVELS FOUND TO BE LOW AND ORAL POTASSIUM
Supplementation WAS GIVEN AND HER TRUE HYPONATREMIA WAS ATTRIBUTED TO
?SIADH. AS HER CHEST X RAY SHOWED MIDDLE LOBE CAVITY OF RT.LUNG USG CHEST
WAS DONE WHICH SHOWED BILATERAL PLEURAL EFFUSION(TAP NOT DONE).ON 3/2/23
OPTHALMOLOGY REFERRAL WAS DONE I/V/O RAISED ICT FEATURES AND ADVICE
FOLLOWED ON 4/2/23 PULMONOLOGY REFERRAL WAS DONE I/V/O X RAY CHANGES AND
ADVICE FOLLOWED.ON 3/2/23 PT MEAN ARTERIAL PRESSURE WAS NOT MAINTAINED AND
WAS STARTED ON INJ.NORAD AND ADJUSTED ACCORDING TO HER BP .X RAY REPORTING
WAS DONE AND SHOWED BILATERAL LUNG CONSOLIDATION WITH MILD
CARDIOMEGALY.PATIENT WAS IRRITABLE DUE TO ?ICU PSYCHOSIS AND ANXIOLYTICS
WERE GIVEN.NEXT DAY AS HER MEAN ARTERIAL PRESSURE WAS NOT MAINTAINED
INJ.DOBUTAMINE 250 MCG IN 50ML NS WAS STARTED AND TAPERED AS HER BP
IMPROVED.PATIENT CONDITION IMPROVED AND
DISCHARGED IN A HEMODYNAMICALLY STABLE CONDITION
Investigation
USG ABDOMEN-NAD
USG CHEST RIGHT MILD PLEURAL EFFUSION
HEMOGRAM ON 3/2/23
HB- 10.7 GM/DL
 Page-4
TLC- 10,300 CELLS/CUMM
PLATELETS- 3.77 LAKHS/CUMM
N/L/E/M/B- 74/16/01/09/00
PCV- 32.3 VOL%
MCV- 85.7 FL
MCH- 28.4 PG
MCHC- 33.1%
RBC- 3.77
IMPRESSION- NORMOCYTIC NORMOCHROMIC BLOOD PICTURE
HEMOGRAM ON 8/2/23
HB- 9.9 GM/DL
TLC- 5700 CELLS/CUMM
PLATELETS- 3.27 LAKHS/CUMM
N/L/E/M/B- 57/26/02/15/00
PCV- 31.4 VOL%
MCV- 88 FL
MCH- 27.7 PG
MCHC- 31.5%
RBC- 3.57
IMPRESSION- NORMOCYTIC NORMOCHROMIC ANEMIA WITH MONOCYTOSIS
2DECHOESD- 5.44CMS
EDD- 6.3CM
DPW- 1CM
EF- 30%
FS- 15%
SEVERETR WITH PAH, MILD MR/AR
GLOBAL HYPOKINETIC
NO AS/MS
SCLEROTIC AV
MODERATE LV DYSFUNCTION
NO DIASTOLIC DYSFUNCTION
 Page-5
REVIEW 2D ECHO ON 6/2/23
GLOBAL HYPOKINETIC
MODERATE TR WITH PAH, MILD MR, MODERATE AR
NO AS/MS, SCLEROTIC AV
EF=30
MODERATE LV DYSFUNCTION
NO DIASTOLIC DYSFUNCTION
IVC SIZE COLLAPSING
MILD DILATED LA/LV
DILATED RA.RV
NO PAH/PE
Treatment Given(Enter only Generic Name)
T. ECOSPRIN GOLD PO HS [75/75/10 MG]
T. MET XL 25MG PO OD
INJ LASIX 20MG IV BD
INJ NORAD DS 2AMP IN 46ML NS IV @ 6ML/HR
FLUID RESTRICTION
O2 SUPLEMENTATION TO MAINTAIN SPO2>94%
Advice at Discharge
T. ECOSPRIN GOLD 75/75/10 MG PO/HS
T.DYTOR 5MG PO/OD 9AM--*--*
T.CARDIVAS 3.125MG PO/OD 8AM--*--*
FLUID RESTRICTION <1LTR/DAY
Follow Up
REVIEW TO GM OP AFTER 1 WEEK/SOS
When to Obtain Urgent Care
IN CASE OF ANY EMERGENCY IMMEDIATELY CONTACT YOUR CONSULTANT DOCTOR OR
ATTEND EMERGENCY DEPARTMENT.
AVOID SELF MEDICATION WITHOUT DOCTORS ADVICE,DONOT MISS MEDICATIONS. In case
of Emergency or to speak to your treating FACULTY or For Appointments, Please Contact:
For Treatment Enquiries Patient/Attendent Declaration : - The medicines prescribed
and the advice regarding preventive aspects of care ,when and how to obtain urgent care have been
explained to me in my own language
SIGNATURE OF PATIENT /ATTENDER
SIGNATURE OF PG/INTERNEE
SIGNATURE OF ADMINISTRATOR
SIGNATURE OF FACULTY
Discharge Date
Date: 8/2/23
Ward: MEDICAL WARD
Unit:IV

The second admission one month later 21-28 March 2023:

This author just realised that the PaJR discussion pasted above after the first admission actually took place in the second admission in a second PaJR group as the second team changed and were unaware of the previous team's approach. Altered sensorium was a more dominant feature in the second admission!

This second admission was case reported (EMR) by Dr Imama here: https://imamamuhmeen.blogspot.com/2023/03/88f-with-recurrent-hypoglycemia-and.html?m=1
Following which the PaJR discussion took place as already pasted above. Pasting the concluding part of the discussion where there's an interjection by the patient's relative thanking the team for their care (actually pasted earlier above).

23/03/23, 11:55 - ~  f PRES is still unclear. Three hypotheses have been proposed till now, which include (i) Cerebral vasoconstriction causing subsequent infarcts in the brain, (ii) Failure of cerebral autoregulation with vasogenic edema, and (iii) Endothelial damage with blood–brain barrier disruption further leading to fluid and protein transudation in the brain. The distinct imaging patterns in PRES are represented in Table Table22 [5]. The reversible nature of PRES has been challenged recently based on new reports of permanent neurological impairment and mortality reaching 15%.

hypertension associated or drug-induced PRES, the effective therapy includes withdrawal of offending agent, immediate control of blood pressure, anti-convulsive therapy and temporary renal replacement therapy (hemodialysis/peritoneal dialysis) if revite link

29/03/23, 16:28 - Dr Rakesh Biswas Sir HOD changed the group name from "88F CAD  Cardiogenic shock Cerebral infarct hyponatremia altered sensorium Telengana PaJR" to "88F Recurrent hypog Cardiogenic shock Cerebral infarct hyponat alt sen Telengana PaJR"

29/03/23, 16:18 - Dr Rakesh Biswas Sir HOD: IMG-20230329-WA0049.jpg (file attached)
This patient was admitted on 21st March and discharged on 28th March yesterday and there was no discussion around her current problems in her previous PaJR group!! @tm  @tm 

29/03/23, 16:21 - Dr Rakesh Biswas Sir HOD: Her current admission due to hypoglycemia and subsequent ordering of a test, morning serum cortisol that shows reduced values should ring a bell around the current 90M with hypoglycemia @tm ?

@tm  Can you share the deidentified serum cortisol reports that were done from outside recently?

29/03/23, 16:24 - Dr Ajay Gen Med Pg: IMG-20230329-WA0048.jpg (file attached)

29/03/23, 16:24 - Dr Ajay Gen Med Pg: IMG-20230329-WA0047.jpg (file attached)

29/03/23, 16:24 - Dr Ajay Gen Med Pg: IMG-20230329-WA0046.jpg (file attached)

29/03/23, 17:59 - Dr Abhinaya, SR. joined using this group's invite link

29/03/23, 18:13 - Dr Aditya Gmed Pgy3 joined using this group's invite link

29/03/23, 18:29 - Dr Aditya Gmed Pgy3: Going out on a limb here - I still think that is a cavity (TB) and the patient has hypotension, Hyponatremia and hypoglycemia with hyperkalemia. Looking like an Addisonian crisis?

Assuming all these were considered already.

Second admission discharge summary (March 21-28 2023)

DEPARTMENT OF GENERAL-MEDICINE
DISCHARGE SUMMARY ***
 Pay Type : Paying
Age/Gender : 89 Years/Female
Address :
Discharge Type: Relieved
Admission Date: 21/03/2023 08:15 PM
Name of Treating Faculty

Diagnosis at discharge:

RECURRENT HYPOGLYCEMIA [RESOLVING ] ? ADRENAL INSUFFICIENCY ? , AKI (PRERENAL)
ON CKD WITH HYPOVOLEMIC SHOCK SECONDARY TO ACUTE GASTROENTERITIS WITH
HEART FAILURE WITH PRESERVED EJECTION FRACTION OF 55% SECONDARY TO CAD
(OLD AWMI) WITH ANAEMIA (NORMOCYTIC NORMOCHROMIC)? NUTRITIONAL,CKD WITH
URINE CULTURE AND SENSITIVITY [ ESCHERICIA COLI SENSITIVE TO NITROFURANTOIN
AND FOSFOMYCIN]

Case History and Clinical Findings

PATIENT WAS BROUGHT TO THE CASUALITY ON 21/3/23 AT 7:57 PM WITH COMPLAINTS OF
-DECREASED SPEECH , SLURRED SPEECH , DROWSY SINCE MORNING
- LOOSE STOOLS SINCE YESTERDAY - 3 EPISODES

HISTORY OF PRESENTING ILLNESS-

PATIENT WAS APPARENTLY ASYMPTOMATIC TILL YESTERDAY THEN SHE DEVELOPED
LOOSE STOOLS , 3 EPISODES , WATERY IN CONSISTENCY , NON BLOOD STAINED , NON
FOUL SMELLING . PATIENT WAS FOUND UNCONSCIOUS , NOT RESPONDING TO VERBAL
COMMANDS AND IN ALTERED SENSORIUM
NO H/O WEAKNESS IN BOTH LIMBS AND NOW DEVELOPED HYPOGLYCEMIA WITH GRBS - 31
MG/DL
NO H/O INVOLUNTARY MOVEMENTS IN BOTH LIMBS
NO H/O FEVER , VOMITINGS , CHEST PAIN , SOB
PAST HISTORY -
K/C/O HEART FAILURE WITH MID RANGE EJECTION FRACTION 42 % SECONDARY TO
ANTERIOR WALL MI WITH PRE RENAL AKI WITH RIGHT LL CONSOLIDATION WITH URETHRAL
CARBUNCLE
CARDIO VASCULAR SYSTEM -
S1 , S2 HEARD
NO MURMURS
RESPIRATORY SYSTEM -
BILATERAL AIR ENTRY PRESENT
NORMAL VESICULAR BREATH SOUNDS PRESENT
ABDOMEN -
SHAPE OF ABDOMEN - SOFT , NON TENDER , BOWEL SOUNDS PRESENT
CENTRAL NERVOUS SYSTEM -
CONCIOUS , COHERENT , COOPERATIVE , WELL ORIENTED TO TIME, PLACE AND PERSON
NO ABNORMALITY DETECTED
COURSE IN THE HOSPITAL -
88 YEARS FEMALE PRESENTED WITH THE ABOVE MENTIONED COMPLAINTS TO THE
CASUALTY PATIENT WAS EVALUATED CLINICALLY AND WITH APPROPRIATE
INVESTIGATIONS WHICH REVEALED RECURRENT HYPOGLYCEMIA. PATIENT WAS GIVEN
25D INFUSION FOR 1 DAY AFTER WHICH THE PATIENT SUGAR STABILIZED AND
ENDOCRINOLOGIST CONSULTATION WAS TAKEN AND ADVICED FOR
1. SERUM CORTISOL
2. SERUM PEPTIDE
3. GROWTH HORMONE LEVELS
4. SMALL FREQUENT MEAL
5. MONITOR GRBS
PATIENT RECOVERED SYMPTOMATICALLY AND WAS DISCHARGED IN STABLE CONDITION
 Page-3
Investigation
HEMOGRAM 
HB- 7.9
TLC- 9900
NEU-73
LYM-19
PCV-26
MCV-86.7
MCH-26.3
MCHC--30.4
RBC-3.00
PLT-2.65
ULTRASOUND REPORT -
E/O 5-6 MM HYPERECHOIC FOCI NOTED IN CONTRACTED GALL BLADDER
2D ECHO -
EF-55
MODERATE AORTIC REGURGITATION , MILD TRICUSPID REGURGITATION WITH PAH; MILD
MR
NO RWMA NO AS/MS , SCLEROTIC AV
GOOD LV SYSTOLIC FUNCTION
DIASTOLIC DYSFUNCTION NO PE
Treatment Given(Enter only Generic Name)
1. IV FLUIDS NS @ 50 ML / HR
2. INJ CIPROFLOXACIN 500 MG IV/BD
3. INJ METROGYL 500ML IV/TID
4. INJ LASIX 20 MG IV/BD
8AM------------4PM
5. TAB ECOSPRIN GOLD 75/75/10 PO/OD AT 8PM
6. SYP LACTULOSE 15 ML PO/HS AT 8PM
7. INPUT / OUTPUT CHARTING
8. GRBS MONITORING 2 HRLY
Advice at Discharge
TAB LASIX 20MG PO/BD
 Page-4
TAB ECOSPRIN GOLD 70/75/10 PO/HS
SYP LACTULOSE 15ML PO/HS
SACHET OF 1 FOSFOMYCIN IN GLASS OF WATER PO ONCE IN 3 DAYS [NEXT DOSE ON
30/3/23 AND NEXT DOSE ON 3/3/23]
Follow Up
REVIEW TO GENERAL MEDICINE OPD AFTER 7 DAYS
REVIEW SOS
When to Obtain Urgent Care
IN CASE OF ANY EMERGENCY IMMEDIATELY CONTACT YOUR CONSULTANT DOCTOR OR
ATTEND EMERGENCY DEPARTMENT.
Preventive Care
AVOID SELF MEDICATION WITHOUT DOCTORS ADVICE,DONOT MISS MEDICATIONS. In case
of Emergency or to speak to your treating FACULTY or For Appointments, Please Contact:
 For Treatment Enquiries Patient/Attendent Declaration : - The medicines prescribed
and the advice regarding preventive aspects of care ,when and how to obtain urgent care have been
explained to me in my own language
SIGNATURE OF PATIENT /ATTENDER
SIGNATURE OF PG/INTERNEE
SIGNATURE OF ADMINISTRATOR
SIGNATURE OF FACULTY
Discharge Date
Date:28/3/23
Ward:AMC
Unit:GENERAL MEDICINE - II

Dr Haripriya entrusted as PI for this project had to collate all her patient's data for final evaluation and analysis of all the patient outcomes in her project and she chose to start with this patient.

Thematic analysis conversations between PaJR team members:

Dyadic conversational transcripts between two project team members 
25/06, 08:16] ALLM: Please share the learning points from this case point wise and divide them into

What was already known to you before your study

What was already known to the world before your study although you didn't know it

What was not known to the world before your study

[25/06, 09:40] Pushed Communicator 1N21: In this case she is a elderly female with no comorbidities came with fluctuations in her sensorium sir..
 *Before my study* I thought that hyponatremia doesn't cause altered sensorium and hyponatremia is common in elderly people and there will be triggers for hyponatremia to present this way..
But *after my study(which is already known to the world)* I found out that, hyponatremia can cause altered sensorium (it can be fluctuating)in this patient,and it's most common in old age which is responsible for recurrent history of falls..


This article showed:
Hospitalised pts with hyponatremia 
Total :100 number.
Elderly:30
Among this,20pts(67%)have no or non specific symptoms of hyponatremia and remaining 10(33%),altered sensorium without FND..
1 person (30%) is having iatrogenic cause for hyponatremia,and 5(17%),had underlying bacterial chest infection leading to hyponatremia....
In this patient,acute cough  from 2 days has triggered her heart failure and to look for chest infection,PA view was ordered initially and later asked for lateral view,to look for middle lobe pathology,and the chest infection caused Hyponatremia in this female,adding to the study...
What am *trying to convey to the world* about this patient is  patients with hyponatremia can present with altered sensorium (which is already known),but that sensorium need not to be constant and can be fluctuating altered sensorium as in this patient..


[25/06, 10:14] ALLM: I would be more interested to know about what you learned about the unique fluctuations of sensorium in this patient. What were the event triggers and timeline of her rising and falling sensorium? Can you share it graphically?

[25/06, 18:48] Pushed Communicator 1N21: I've shared my learning points sir

[25/06, 18:48] Pushed Communicator 1N21: Anything more in this case sir

[25/06, 19:09] Rakesh Biswas: Would be more interested to know about what you learned about the unique fluctuations of sensorium in this patient. What were the event triggers and timeline of her rising and falling sensorium? Can you share it graphically?

[25/06, 19:10] Pushed Communicator 1N21: Sir
How can I draw the timeline of events graphically sir 
As you will be saying that,our discussion should be starting from the beginning (when the pt gets admitted)
The similar way,we discussed the case bedside sir.
There are lot more cases of mine discussed at the time of admission itself

[25/06, 19:11] ALLM : It's the patient timeline we regularly share in the form of soap notes in the fever chart

[25/06, 19:12] Pushed Communicator 1N21: Yes.
It's already there in the blog shared in the morning

[25/06, 19:13] ALLM: I didn't see the:

Event triggers and timeline of her rising and falling sensorium in relation to her sodium values

PaJR team based learning:

[26/06, 12:04] Sai Charan Kulkarni 2020 KIMS Pg: *Independent Ai Researcher Analysis of the Blog "Case Report Form in BEHR Blended EMR"*

*Introduction*
The blog post titled "Case Report Form in BEHR Blended EMR" discusses the integration and functionality of case report forms (CRFs) within the BEHR (Blended Electronic Health Record) system. It provides insights into the implementation, benefits, and potential challenges of using CRFs in a blended electronic medical records (EMR) environment.

*Thematic Analysis*

1. **Integration and Implementation**
   - **Seamless Integration**: The BEHR system integrates CRFs to streamline data collection and patient management processes. This integration allows for real-time data entry and retrieval, which enhances clinical efficiency.
   - **Customizable Templates**: The system supports customizable CRF templates, enabling healthcare providers to tailor forms to specific study requirements or clinical needs. This flexibility is crucial for accommodating various research and clinical scenarios.

2. **Benefits of CRFs in BEHR**
   - **Enhanced Data Accuracy**: The use of CRFs within BEHR improves the accuracy of data collection by minimizing manual entry errors and ensuring standardized data capture.
   - **Improved Patient Care**: Real-time data availability through BEHR allows for more informed clinical decisions, leading to better patient outcomes.
   - **Facilitation of Clinical Research**: CRFs in BEHR support clinical research by providing a structured way to collect and analyze patient data, which is essential for observational studies and clinical trials.

3. **Challenges and Solutions**
   - **User Training and Adaptation**: One challenge is ensuring that healthcare providers are adequately trained to use the new system. The blog suggests ongoing training and support to mitigate this issue.
   - **Data Privacy and Security**: The integration of CRFs into an EMR system raises concerns about data privacy and security. The BEHR system addresses these concerns through robust encryption and access controls.

4. **Future Prospects**
   - **Scalability**: The blog highlights the potential for scaling the BEHR system to accommodate larger datasets and more complex clinical studies.
   - **Interoperability**: There is an emphasis on improving interoperability with other health information systems, which would facilitate more comprehensive data sharing and collaboration across different healthcare institutions.

*Conclusion*
The blog post provides a comprehensive overview of the integration of case report forms in the BEHR Blended EMR system, highlighting the benefits of enhanced data accuracy, improved patient care, and facilitation of clinical research. It also acknowledges the challenges of user training and data security, suggesting solutions such as ongoing education and robust security measures. The potential for scalability and improved interoperability positions the BEHR system as a promising tool for future healthcare and research applications.
[26/06, 12:11] Rakesh Biswas: 👏👏For the AI LLM

Not sure about the AI researcher 😅
[26/06, 12:15] Rakesh Biswas: Which LLM is this?

It has completely ignored the patient's outcomes and focused only on our novel system of EHR driven case reporting aka  case report form (in short CRF) traditionally in patient driven clinical trials.

Nevertheless this is also an important theme to explore

[26/06, 12:34] Chandana KIMS 2020 SR: From this case report I understand that she was admitted two times.

Feb 2023 she was treated for HfrEF, Anterior wall MI, hyponatremia secondary to SIADH, hypokalemia and pneumonia

In 2nd admission the significant problem was altered sensorium secondary to ? Uremia ? Hypoxia with suspected ILD and hypotension when adrenal crisis was also considered.

I dint understand why PRES was considered.

Complexity of managing elderly female with altered sensorium with multiple complex etiologies and stressors such as hypoxia, uremia, pneumonia +\-sepsis, MI with heart failure, hypotension ,?neuro degeneration. All these making the cause of altered sensorium uncertain

[26/06, 12:47] Rakesh Biswas: Good point! 

Can you scroll up to the PaJR data here and share why we (I guess it was me alone) thought of pres?

I have lost all past data in my new phone

[26/06, 12:50] Sai Charan Kulkarni 2020 KIMS Pg: Problem could be in the prompt. Just rephrased my prompt, this is what I get.. 

### Independent Researcher Clinical Analysis of Patient-Related Outcomes in the Blog "Case Report Form in BEHR Blended EMR"

#### Introduction
The blog post "Case Report Form in BEHR Blended EMR" discusses a detailed clinical case, including the patient's medical history, diagnostic procedures, treatment plan, and outcomes. This analysis focuses on patient-related outcomes, examining how the use of the BEHR system influenced the patient’s overall health, quality of life, and long-term prognosis.

#### Patient-Related Outcomes

1. **Health Outcomes**
   - **Symptom Relief**: Post-treatment, the patient experienced significant relief from initial symptoms such as fatigue, shortness of breath, and chest pain. This was primarily due to effective coronary intervention and optimized medical management.
   - **Control of Chronic Conditions**: Improved control of diabetes and hypertension was observed, with stabilized blood glucose and blood pressure levels. This outcome was facilitated by the BEHR system’s ability to track and adjust treatment plans in real-time.

2. **Quality of Life**
   - **Physical Health**: The patient reported increased energy levels and physical capacity, allowing for greater engagement in daily activities and exercise. This improvement is attributed to the comprehensive management of their cardiovascular and metabolic conditions.
   - **Mental Health**: Effective symptom management and reduced health-related anxiety contributed to better mental well-being. The patient benefited from continuous monitoring and support, which provided reassurance and improved overall mental health.

3. **Adherence and Compliance**
   - **Medication Adherence**: The BEHR system’s real-time monitoring and reminders helped the patient adhere to their medication regimen, which is crucial for managing chronic conditions. Regular follow-ups and education reinforced the importance of compliance.
   - **Lifestyle Changes**: The patient successfully implemented recommended lifestyle modifications, including dietary changes and increased physical activity. The support and education provided through the BEHR system played a significant role in sustaining these changes.

4. **Clinical Outcomes**
   - **Cardiovascular Health**: Successful percutaneous coronary intervention (PCI) led to improved cardiovascular outcomes, with no significant post-operative complications. The patient's heart function stabilized, as evidenced by follow-up echocardiograms.
   - **Long-Term Prognosis**: The patient’s long-term prognosis improved due to the combined effects of intervention, medication management, and lifestyle changes. Continuous monitoring via the BEHR system ensures that any potential issues can be promptly addressed, enhancing long-term health outcomes.

5. **Patient Satisfaction**
   - **Engagement and Satisfaction**: The patient expressed high satisfaction with the care received, highlighting the ease of communication with healthcare providers and the support from the BEHR system. This engagement is crucial for sustained health improvements.
   - **Empowerment**: Access to personal health data and educational resources empowered the patient to take an active role in managing their health, leading to better outcomes and increased satisfaction with the care process.

#### Conclusion
The clinical analysis of patient-related outcomes in the blog "Case Report Form in BEHR Blended EMR" demonstrates the significant positive impact of the BEHR system on the patient’s health, quality of life, and long-term prognosis. Enhanced symptom relief, better control of chronic conditions, improved mental and physical health, and high patient satisfaction are key outcomes observed. The integrated approach facilitated by the BEHR system underscores its potential to transform patient care through continuous support, accurate data collection, and effective treatment management.
[26/06, 12:52] Sai Charan Kulkarni 2020 KIMS Pg: Based on GPT 4 sir.

[26/06, 13:07] Rakesh Biswas: It's clearly hallucinating! 😅

AI hallucinations in PaJR thematic analysis is the title of our next paper

Themes emerging:

Elderly woman with altered sensorium

Clinical complexity:

Multiple comorbidities and organ failure

Diagnostic uncertainty:

Multiple possibilities for altered sensorium:

Metabolic (possible acute trigger):

Hypoglycemia

Hyponatremia

Hypoxia

Uremia

Structural (possible chronic vasculopathic process):

PRES 

Neurodegenerative 

Therapeutic uncertainty:

Each organ failure such as cardiac and vascular instability was tackled with standard of care 

Epilogue and final outcome:
The patient reportedly died at home shortly after discharge from her second hospital admission 


Sunday, June 23, 2024

37M Dyspepsia NUD GAD 7 years Metabolic syn WB PaJR

Discharge summary:


Age/Gender
:35 Years/Male

Discharge Type

Admission Date: 29/10/2022 12:11 PM


Diagnosis
GENERALIZED ANXIETY DISORDER GAD
NUD, tinea 

Case History and Clinical Findings
35 yr male came with chief complaints of- Epigastric pain since 5 yrs

HOPI:Patient was apparently asymptomatic 5yrs ago then he developed epigastric pain he went to local hospital 5yrs ago where he was given medication and again after 4 years he presented with loin pain went to local hospital where he was diagnosed with renal calculi and now presented with epigastric pain since 1 month
,insidious in onset ,pricking type,non radiating, reduced after taking food, burning sensation after taking spicy food,relievedaftermedication.-Nofever,vomiting,,diarrhoea 

Past history:Not a known case of DM,HTN, Asthma, Epilepsy,CVA,CAD,TBPresent history:Appetite - NornalDiet-MixedSleep -AdequateBowel and bladder habits -RegularNo addictionsGeneral Examination:Patient is conscious, coherent, co-operativeWell oriented to time, place and person
Moderately built and nourished
-Nopallor,icterus,cyanosis,clubbing,pedaloedema,lymphadenopathy vitals:
pr:87bpm bp:130/80mmhg temp:98.1 rr:14cpm


Systemic Examination:




Abdominal Examination:Inspection:-Shape of abdomen - slightly distended- Umbilicis - Central-All quadrants moving equally with respiration- No scars,sinuses, engorged veins,dilated vesselsPalpation:- No local rise of temperature,no tenderness- No organomegalyAuscultation:-Bowel sounds heardCVS: S1S2 PresentRS: BAE Present,NVBS

Brief course in hospital:

35yr male came  with chief complaints of epigastric painsince 1month, insidious in onset ,pricking type,non radiating, reduced after taking food, burning sensation after taking spicy food,relieved after medication.gastro opinion was taken was advised upper gi endoscopy was done which shows non erosive antral gastritis .ortho opinion was taken advised x ray of foot and knee which appears to be normal.derma opinion was taken for hypopigmented patches, taenia cruris was diagnosed ,topical anti fungals are given,

Investigation

CBP:
HB-13.6 TLC:9,000 RBC:5.13 PLC:2.73


Treatment Given(Enter only Generic Name)


T.PAN 40MG PO/OD
LULIFINE CREAM OD
EBERNATE CREAM OD
T.TECZINE PO/OD


Advice at Discharge
T.PAN 40MG PO/OD X 5 DAYS
T.HIFENAC PO/BDX 5DAYS
T.SHELCAL PO/OD X 30DAYS
T.NEUROKIND PO/OD X 30DAYS
LULIFINE CREAM X 1WEEK AT NIGHT
EBERNATE CREAM X 1WEEK AT MORNING


Follow Up
REVIEW AT GENERAL MEDICINE OP
When to Obtain Urgent Care

 in my own language
SIGNATUREOFPATIENT/ATTENDER SIGNATURE OF PG/INTERNEE SIGNATURE OF ADMINISTRATOR SIGNATURE OF FACULTY


Discharge Date Date:09/11/22 Ward:MEDICALWARD
Unit:6

Recent follow up UDLC dyadic pre PaJR:

[22/06, 00:21] Pt Advocate 37M GAD NUD WB: 𝙎𝙞𝙧 𝙖𝙢𝙖𝙧 𝙋𝙚𝙩𝙚𝙧 𝙥𝙖𝙗𝙡𝙚𝙢𝙩𝙖 𝙖𝙗𝙖𝙧 𝙝𝙘𝙝𝙚 𝙩𝙖𝙞 𝙠𝙖𝙡𝙠𝙚 𝙪𝙨𝙜 𝙧𝙞𝙥𝙤𝙩 𝙠𝙤𝙧𝙗𝙤 𝙧𝙞𝙥𝙤𝙩 𝙩𝙖𝙠𝙞 𝙖𝙥𝙣𝙖𝙠𝙚 𝙥𝙖𝙩𝙝𝙖𝙗𝙤

[22/06, 14:52] BLLM: 5 bochor aager byatha ta aekhon kemon ache?

[22/06, 15:24] Pt Advocate 37M GAD NUD WB: 𝘽𝙚𝙩𝙝𝙖𝙩𝙖 𝙖𝙠𝙝𝙖𝙣 𝙣𝙚𝙞 𝙩𝙗𝙚 𝙖𝙡𝙥𝙤 𝙠𝙝𝙚𝙡𝙚𝙞 𝙥𝙚𝙩 𝙫𝙤𝙧𝙚 𝙅𝙖𝙮 𝙖𝙧 𝙨𝙘𝙞𝙙𝙞𝙩𝙞 𝙝𝙖𝙘𝙚 𝙡𝙞𝙫𝙖𝙧𝙚𝙧 𝙟𝙖𝙮𝙜𝙖𝙮 𝙝𝙖𝙡𝙠𝙖 𝙗𝙚𝙩𝙝𝙖 𝙝𝙖𝙮 𝙤 𝙩𝙤𝙮𝙡𝙚𝙩𝙚𝙧 𝙨𝙤𝙢𝙤𝙮 𝙟𝙖𝙡𝙖 𝙝𝙤𝙮

[22/06, 18:23] Pt Advocate 37M GAD NUD WB: 𝙎𝙞𝙧 𝙖𝙢𝙖𝙧 𝙪𝙨𝙜 𝙧𝙞𝙥𝙤𝙩𝙖 𝙠𝙚𝙢𝙤𝙣 𝙖𝙘𝙝𝙚

[22/06, 18:26] BLLM: USG te apnar somosya ta bojhar kotha noi

[23/06, 18:38] Pt Advocate 37M GAD NUD WB: 𝙎𝙞𝙧 𝙖𝙠𝙝𝙖𝙣 𝙖𝙢𝙖𝙧 𝙠𝙖𝙧𝙤𝙣𝙞𝙤 𝙠𝙞 𝙖𝙘𝙝𝙚

[23/06, 18:42] BLLM: Apnar jonye ekta group toiri kore debo shekhane doinondin janaben apnar khabar plate er chobi ebong ghontai ghontai ki ki korchen anekata jemon ekhane baki ra ki bhabe janacche dekhte paren 👇

[23/06, 18:53] Pt Advocate 37M GAD NUD WB: 𝙎𝙞𝙧 𝙖𝙢𝙖𝙧 𝙪𝙨𝙜 𝙧𝙞𝙥𝙤𝙩𝙖 𝙙𝙚𝙠𝙝𝙚 𝙘𝙜𝙚𝙣


[23/06, 18:57] BLLM: 👆Aagei dekhe janiyechi

[23/06, 18:58] BLLM: 👆 Gotokal ghontai ghontai sokal theke raat obdhi ki korechilen janaben ebong kone somoi byatha hoyechilo shetao janaben

Sunday, June 9, 2024

UDLCO : Faces of Semaglutide and it's conversational peer review in journal clubs

UDLCO summary :


New pharmacological intervention with extended indications for diabetes, weight gain as well as heart failure in the form of a novel GLP1 inhibitor recently flying off the shelves has raised eyebrows and the journal club raises certain issues. There is also some discussion around a typical face that Semaglutide produces. 


UDLC transcripts :

Metacognitist metapsych group journal club conversational transcripts logged here earlier :



[4/9, 12:35 AM] Pediatric endo NJ :

 Semaglutide in HFpEF 



[4/9, 8:28 AM] Rakesh Biswas: We left this journal club midway with our students around the question of trying to understand the clinical significance of the statistically significant changes in :

"in the mean KCCQ-CSS as 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and  mean percentage change in body weight as −9.8% with semaglutide and −3.4% with placebo"!

The next step was reviewing all the points in the KCCQ-CSS to understand the clinical significance of it's numbers



[4/9, 8:59 AM] Rakesh Biswas: Would it be possible for you to share the full text. 

I realized that our students had been discussing a full text of an earlier 2022 study published open access but probably ignored this as there was no full text


[4/9, 9:20 AM] Rakesh Biswas: Journal club  conversational critical appraisal and the point where we got stuck shown in the transcripts below :


an observational, retrospective, real-world study on obese outpatients with T2D and chronic HF at the HF Units of Internal Medicine Department at the Hospital Regional Universitario de Málaga in Málaga; the Hospital Costal de Sol, in Marbella; and the Hospital Helicopteros Sanitarios, in Marbella, Spain.

P - total of 136 patients were included ( out patients ) 

I - safety and efficacy of semaglutide as management for obesity in TY2DM and HF. 

C - clinical, laboratory and therapeutic variables of pre and post Semaglutide therapy at 3, 6, 12 months in same patients. 

O - From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy.


[4/3, 8:42 AM] Sai Charan Kulkarni 2020 KIMS Pg: *primary endpoint* :  was to evaluate the clinical efficacy in the HF health status, as determined by the improvement in the total symptom score on the Spanish version of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (19), reduction in the New York Heart Association (NYHA) classification, and reduction in NT-pro-BNP levels. 

*Secondary outcomes* : included the glycemic efficacy, as determined by the reduction in HbA1c levels and the proportion of patients who achieved good glycemic control (HbA1c <7%) prior to starting semaglutide and at 3, 6, and 12 months; weight loss (changes in body weight, BMI, and waist circumference); de-intensification of T2D treatment (reduction in number of daily glucose-lowering drugs and/or insulin doses) and HF treatment (decline in number of antihypertensive agents, beta-blockers and diuretics); and the safety (adverse drug reactions, need to discontinue semaglutide due to adverse events, 3P-MACE, emergency department visit because of HF decompensation (from one year before initiation), hospitalizations (from one year before initiation), and mortality (from one year before initiation).


[4/3, 8:50 AM] Rakesh Biswas: Can you share the break up of the symptom score so that we can understand how clinically significant are the differences portrayed by the numbers in the total symptom score here :

As in what's the clinical significance between 59.0 ± 24.1 vs 79.9 ± 28.4 points? Will only become clear when we see what those points stand for? 


[4/3, 8:53 AM] Rakesh Biswas: Share the numbers for these :

"Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined."

Also numbers for :

How many had a de-intensification of antidiabetic therapy?"


[4/3, 9:12 AM] Sai Charan Kulkarni 2020 KIMS Pg: All numbers shared here sir. 

[4/3, 9:13 AM] Rakesh Biswas: Discuss their clinical significance

[4/3, 9:15 AM] Rakesh Biswas: Where's the division here between the two groups?


[4/3, 9:16 AM] Rakesh Biswas: Oh just realised there's no comparator!! 😬🧐

What's the point?

[4/3, 9:18 AM] Rakesh Biswas: How can frontiers publish such a study without a comparator especially when it's not a qualitative study either providing insights?

[4/3, 9:19 AM] Rakesh Biswas: Let's look for some RCTs for Semaglutide efficacy?

[4/9, 9:41 AM] NJ : @Rakesh: Here you go.

[4/9, 10:35 PM] Rakesh Biswas: Went through this NEJM study full text today thanks to @⁨NJ  and also through the full text of the Kansas City Cardiomyopathy
 questionnaire from 2000 and as suspected there are quite a few issues!


For a start, the questionnaire says it's a 2 week recall and the study evaluates it after a year, which means the patients are simply telling us what happened in the last two weeks, not one year? 

Also what would change with Semaglutide in a year when answering KCCQ questions like the one below 👇

"Heart failure symptoms can worsen for a number of reasons. How sure are you that you know what to do, or whom to call, if your heart failure gets worse?



[4/10, 12:52 AM] NJ : @Rakesh: I am not sure I understand the issues you’re referring to.

KCCQ-CSS is a validated patient reported outcome measure - although it represents a 2-week recall at any time point, it has been shown to be valid, reproducible, and sensitive to clinical changes in patients with systolic dysfunction, HFpEF, and other conditions. 

So, in this case the pre-randomization score can be taken to be representative of the baseline situation, and the end of study score representative of the situation after 52 weeks of treatment. The primary efficacy endpoint is typically assessed at a pre specified discrete time point after a specific period of intervention. 

From that perspective, the use of KCCQ-CSS is appropriate, despite the fact that it was measured at Weeks 20 and 36 too. The time course (Figure 1A) supports the reality of improvement at week 52. 

The same is seen for weight. The trajectory of weight loss (Figure 1B) supports the between-group difference at week 52.

Evolving demand for more and more Semaglutide like drugs: 

From "couch potato to couch carrots" appears to be the current drug development flavor/fervor 😅👇

 [5/5, 2:47 AM] +1 (832) Nearly half of Americans  are awaiting prescription for one of these GLP1 agonists 
(market projected to be worth as much as $100 billion by 2030.)
There is lot of bio pharmaceutical investment in this field and science is moving fast to develop new designer molecules with triple agonists ( GLPI , GIP and glucagon/ AI models being used to accelerate drug development 
Amgen has partnered with NIVDIA for drug development/ generative biology allows for the generation of new protein-based drugs that have desired structures and properties based on existing protein data inputs.
We will see flood of GLP dual and triple agonists in next few years . 
April 2024, more than 50 glucagon-like peptide-1 receptor agonists  are in clinical development for type 2 diabetes, obesity, or both. 
Loss of lean body mass and sarcopenia remains concern with GLP- 1 
Few exciting molecules in development , which reduce fat mass and increase muscle mass. No need to exercise, 
Never heard of this before exerkine analogues (peptide that is released during exercise that improves metabolic and muscle function. ) can be synthesized and being developed for obesity, one stop solution for couch potatoes
Azelaprag is one of these drugs undergoing trials. Then there is Class of myostatin inhibitors.
A myostatin inhibitor called taldefgrobep alfa, undergoing trials to weight loss and increased lean tissue.
I believe, research is exploding in the field of obesity/ to its advantage is AI/ generative biology / this is unlikely to fizzle out like cox inhibitors

[5/4, 4:16 AM] +1 (301): Almost all weight reduction drugs have many different side effects reported, but in the prolong duration and long term side effects or complications data buried or under reported. Pharmaceutical industries wrecking money from these products and have to take responsibility for honest open monitoring and provide correct data to the public.



[5/4, 6:01 AM] Endocrinologist NJ: None of these studies looked at hand grip and/or 6-min walk to test muscle strength. 

What I’m saying is that losing muscle (as determined by DEXA) may not be a bad thing, unless there’s loss of strength.  

Talking about just muscle mass w/o data on strength and calling that sarcopenia is not appropriate. And, probably just a gimmick. 

Most of the agents that have been tested for sarcopenia (e.g., age-related sarcopenia) have shown improvements in muscle mass without appreciable improvements in strength.


[5/4, 9:50 AM] Rakesh Biswas: Is Sarcopenia the reason for ozempic face? 



Some of my patients who have given up sugar totally have also shared their before after facial pictures with me that suggests similar facial changes. I would wager the facial changes could be fat reduction. Any review of literature data on this?


[5/4, 10:49 AM] +44: Won't be surprised in few years time , this will be like cox inhibitor drugs and withdrawn






October 28 update:

Lancet review:

[27/10, 20:23] Rakesh Biswas: "The crucial roles of skeletal muscle have come to the forefront of public attention due to data on the use of GLP-1 receptor agonists, which are effective for weight loss, but can cause substantial muscle loss. Studies suggest muscle loss with these medications (as indicated by decreases in fat-free mass [FFM]) ranges from 25% to 39% of the total weight lost over 36–72 weeks.2 This substantial muscle loss can be largely attributed to the magnitude of weight loss, rather than by an independent effect of GLP-1 receptor agonists, although this hypothesis must be tested. By comparison, non-pharmacological caloric restriction studies with smaller magnitudes of weight loss result in 10–30% FFM losses.3 In context, on an annual basis, the decline in muscle mass with GLP-1 receptor agonists is several times greater than what would be expected from age-related muscle loss (0·8% per year based on 8% muscle loss per decade from ages 40–70 years)."

Unquote

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00272-9/abstract?dgcid=raven_jbs_etoc_email


[27/10, 21:03] Pediatric Endocrinologist NJ: However, muscle strength has not been assessed with GLP-1 RAs-induced weight loss. 
Loss of muscle mass + decrease in muscle function = sarcopenia. 
Age-related loss of muscle mass is sarcopenia, because it is associated with loss of muscle function. 
Weight-loss meds associated decrease in muscle mass may or may not be sarcopenia. Well designed studies are needed… first, to see if objective decreases in muscle function occur, and then to assess if similar/matched loss of muscle from other weight loss modalities (e.g., bariatric surgery) cause similar loss in muscle function.

November 2024 Update on another GLP1 inhibitor used again for heart failure perhaps to make the cut as demonstrated in sglt2 inhibitor! 

Conversational Transcripts:

[17/11, 06:54] r: This is yesterday's hot cake burning social media 👇



[17/11, 06:58] r: And here are the influencers


[17/11, 07:00] rb: 


[17/11, 07:04]rb: @⁨Meta AI⁩ can you access the full text and analyse this study data in the PICO format taking care to share the absolute numbers and not relative percentages (luckily it's catching up with the current journal articles too and this added prompt may hopefully become redundant soon). If you can't access the full text through the URL below 👇


then I can share the full text PDF although I'm not sure if you have begun reading PDF in the WhatsApp interface
[17/11, 07:05] Meta AI: Unfortunately, I remain unable to access the study directly through the URL, but I can still assist.

To proceed, please provide:

1. Study title
2. Relevant text or data excerpts (you can copy-paste)
3. Specific analysis requests (e.g., PICO format, focus areas)

This will enable me to provide the desired analysis.

If you share the full text, I'll ensure to:

- Extract absolute numbers (not relative percentages)
- Analyze in PICO format
    1. Population (P)
    2. Intervention (I)
    3. Comparator (C)
    4. Outcomes (O)

Let's begin!


[17/11, 07:22] rb : I used Google LM (free version) to do the PICO prompt I gave meta AI after first trying the free version of ChatGPT which didn't work (for free)!👇

## PICO Analysis of Tirzepatide Study Data

Here is a PICO analysis of the tirzepatide study data from the provided excerpt from the New England Journal of Medicine, taking care to use absolute numbers instead of percentages:

* **Population (P):** The study included **731** patients with:
    * Chronic heart failure (New York Heart Association class II to IV)
    * A left ventricular ejection fraction of at least 50%
    * A body mass index (BMI) of at least 30 (obesity)
    * A 6-minute walk distance of between 100 and 425 m
    * A Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) of 80 or lower

* **Intervention (I):** The intervention group received tirzepatide subcutaneously, starting at a dose of 2.5 mg per week and increasing by 2.5 mg every 4 weeks (if tolerated) up to a maximum dose of 15 mg per week. **364** patients were assigned to the tirzepatide group.

* **Comparison (C):** The comparison group received a placebo. **367** patients were assigned to the placebo group.

* **Outcomes (O):** The study assessed two primary outcomes:
    * **Composite of adjudicated death from cardiovascular causes or a worsening heart-failure event:** This occurred in **36 patients** in the tirzepatide group and **56 patients** in the placebo group.
        * **Worsening heart-failure events** occurred in **29 patients** in the tirzepatide group and **52 patients** in the placebo group.
        * **Adjudicated death from cardiovascular causes** occurred in **8 patients** in the tirzepatide group and **5 patients** in the placebo group.
    * **Change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS):** At 52 weeks, the mean change in the KCCQ-CSS was 19.5 points in the tirzepatide group and 12.7 points in the placebo group.

The study also assessed several key secondary outcomes, including:

* **Change in the 6-minute walk distance at 52 weeks:** The mean increase in the 6-minute walk distance was **26.0 m** in the tirzepatide group and **10.1 m** in the placebo group.
* **Percent change in body weight at 52 weeks:** The mean percent change in body weight was **-13.9%** in the tirzepatide group and **-2.2%** in the placebo group.
* **Percent change in the high-sensitivity CRP level at 52 weeks:** The mean percent decrease in the high-sensitivity CRP level was **-38.8%** in the tirzepatide group and **-5.9%** in the placebo group.

The median duration of follow-up for the study was **104 weeks**. The authors concluded that tirzepatide reduced the risk of cardiovascular death or worsening heart failure and improved health status in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.


[17/11, 07:23] : It appears that google LM may not suffer from the same kind of number dyslexia as meta AI! Will need to play with it more



Tuesday, June 4, 2024

Dr Nupur Sarkar CV

 MBBS, AIIMS, New Delhi 1996


MD Pediatrics AIIMS, New Delhi 2000


 

Senior Resident 2000-2001

Asst Prof 2002-2008

Associate Prof 2008-2014

Faculty Of Homeopathy 2023